AMPT/ Demser

PreclinicalSmall molecule

UUniversity of Bern

AMPT/ Demser is one of 8 small molecule programs targeting Bulimia Nervosa. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bulimia NervosaActive, not recruiting

Bulimia NervosaPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Bulimia Nervosa

#DrugCompanyPhaseTrials

Prometrium

Ferring

Approved

—2

Acetadote

AArbor Pharmaceuticals, Inc.

Lioresal

1 4

Namenda

AbbVie

Preclinical

1 5

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

3 6

Benadryl

PParkedale

Preclinical

1 7

MDMA-AT

HHerzog Hospital

Phase 1

1 8

AMPT/ Demser

UUniversity of Bern

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bulimia Nervosa1 trial

Neural Response to Catecholamine Depletion in Subjects Suffering From Bulimia Nervosa in Their Past and Healthy Controls

Suspended·UUniversity of Bern·N/A·NCT02179814·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AMPT/ Demser. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AMPT/ Demser compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AMPT/ Demser. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Bern company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Bern

AMPT/ Demser

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bulimia Nervosa1 trial

References

Drug Info

Quick Facts

Related News